BAM
AMPH icon

Belpointe Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Belpointe Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$563 – 714
2023
Q1 		$563 Buy
+15
New +$492 ﹤0.01% 3576

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Belpointe Asset Management's AMPH Position: Q2 2023 in Review

Belpointe Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2023, closing a stake of 15 shares — an estimated $563 sold.

Belpointe Asset Management first reported a position in AMPH in Q1 2023 and held it in 1 quarter. The position peaked at $563 in Q1 2023. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2023.

  • Belpointe Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 15 Amphastar Pharmaceuticals shares in Q2 2023, an estimated $563.
  • Belpointe Asset Management first reported a position in Amphastar Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Amphastar Pharmaceuticals position peaked at $563 in Q1 2023.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.